In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Protected dosing program. Additional individuals will likely be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase C, https://williamg443rcm6.evawiki.com/user